Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.310
-0.010 (-0.76%)
At close: Feb 27, 2026, 4:00 PM EST
1.310
0.00 (-0.01%)
After-hours: Feb 27, 2026, 7:52 PM EST
Akebia Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 236.2 | 160.18 | 194.62 | 292.48 | 211.65 | Upgrade
|
| Revenue Growth (YoY) | 47.46% | -17.70% | -33.46% | 38.19% | -28.17% | Upgrade
|
| Cost of Revenue | 42.86 | 26.15 | 39.76 | 22.5 | 81.49 | Upgrade
|
| Gross Profit | 193.34 | 134.03 | 154.86 | 269.99 | 130.16 | Upgrade
|
| Selling, General & Admin | 107.48 | 106.55 | 100.23 | 138.6 | 174.14 | Upgrade
|
| Research & Development | 62.36 | 37.65 | 63.08 | 129.99 | 147.85 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | 36.04 | 36.04 | 36.04 | 36.04 | Upgrade
|
| Operating Expenses | 169.84 | 180.24 | 199.35 | 304.63 | 358.03 | Upgrade
|
| Operating Income | 23.5 | -46.21 | -44.5 | -34.64 | -227.88 | Upgrade
|
| Interest Expense | -24.18 | -18.19 | -6.03 | -15.69 | -20.02 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0.07 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.04 | -0.24 | 0.89 | 3.15 | 2.41 | Upgrade
|
| EBT Excluding Unusual Items | -3.72 | -64.63 | -49.64 | -47.18 | -245.42 | Upgrade
|
| Merger & Restructuring Charges | - | -0.06 | -0.18 | -15.93 | -21.58 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.02 | Upgrade
|
| Asset Writedown | - | -4.21 | -1.58 | -30.24 | -15.05 | Upgrade
|
| Other Unusual Items | - | -0.52 | -0.52 | -0.87 | - | Upgrade
|
| Pretax Income | -3.72 | -69.41 | -51.93 | -94.23 | -282.02 | Upgrade
|
| Income Tax Expense | 1.62 | - | - | - | - | Upgrade
|
| Net Income | -5.35 | -69.41 | -51.93 | -94.23 | -282.02 | Upgrade
|
| Net Income to Common | -5.35 | -69.41 | -51.93 | -94.23 | -282.02 | Upgrade
|
| Shares Outstanding (Basic) | 257 | 211 | 187 | 183 | 166 | Upgrade
|
| Shares Outstanding (Diluted) | 257 | 211 | 187 | 183 | 166 | Upgrade
|
| Shares Change (YoY) | 21.91% | 12.53% | 2.56% | 10.14% | 19.85% | Upgrade
|
| EPS (Basic) | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 | Upgrade
|
| Free Cash Flow | 59.89 | -40.69 | -23.38 | -73.27 | -253.02 | Upgrade
|
| Free Cash Flow Per Share | 0.23 | -0.19 | -0.13 | -0.40 | -1.52 | Upgrade
|
| Gross Margin | 81.86% | 83.68% | 79.57% | 92.31% | 61.50% | Upgrade
|
| Operating Margin | 9.95% | -28.85% | -22.86% | -11.84% | -107.67% | Upgrade
|
| Profit Margin | -2.26% | -43.33% | -26.68% | -32.22% | -133.25% | Upgrade
|
| Free Cash Flow Margin | 25.36% | -25.40% | -12.02% | -25.05% | -119.55% | Upgrade
|
| EBITDA | 24.77 | -8.7 | -6.87 | 3.06 | -189.91 | Upgrade
|
| EBITDA Margin | 10.49% | -5.43% | -3.53% | 1.04% | -89.73% | Upgrade
|
| D&A For EBITDA | 1.27 | 37.5 | 37.63 | 37.7 | 37.97 | Upgrade
|
| EBIT | 23.5 | -46.21 | -44.5 | -34.64 | -227.88 | Upgrade
|
| EBIT Margin | 9.95% | -28.85% | -22.86% | -11.84% | -107.67% | Upgrade
|
| Revenue as Reported | 236.2 | 160.18 | 194.62 | 292.48 | 211.65 | Upgrade
|
| Advertising Expenses | - | 4.6 | 1 | 6.7 | 8.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.